Advertisement
BFRI vs CTOR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BFRI is a Hold and CTOR is a StrongBuy.
Momentum Indicator for BFRI turns positive, indicating new upward trend
BFRI saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 73 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BFRI's RSI Indicator exited the oversold zone, 22 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for BFRI just turned positive on October 26, 2026. Looking at past instances where BFRI's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Following a +5.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where BFRI advanced for three days, in 190 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BFRI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BFRI entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.065) is normal, around the industry mean (6.379). P/E Ratio (-1.926) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.307) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. BFRI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BFRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
CTOR's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for CTOR moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 13 similar instances when the indicator left oversold territory. In 12 of the 13 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 24 of 42 cases where CTOR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for CTOR just turned positive on November 10, 2026. Looking at past instances where CTOR's MACD turned positive, the stock continued to rise in 16 of 36 cases over the following month. The odds of a continued upward trend are 44%.
Following a +10.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTOR advanced for three days, in 93 of 117 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CTOR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
CTOR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CTOR crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
The 50-day moving average for CTOR moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CTOR entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.334) is normal, around the industry mean (6.379). P/E Ratio (-1.061) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (12.547) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CTOR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
| BFRI | CTOR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 57% |
| Momentum ODDS (%) | 1 day ago 88% | N/A |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 44% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 48% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 81% | 3 days ago 79% |
| Declines ODDS (%) | 11 days ago 90% | 8 days ago 88% |
| BollingerBands ODDS (%) | N/A | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BFRI’s FA Score shows that 1 FA rating(s) are green while CTOR’s FA Score has 1 green FA rating(s).
- BFRI’s FA Score: 1 green, 4 red.
- CTOR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BFRI’s TA Score shows that 4 TA indicator(s) are bullish while CTOR’s TA Score has 5 bullish TA indicator(s).
- BFRI’s TA Score: 4 bullish, 3 bearish.
- CTOR’s TA Score: 5 bullish, 5 bearish.
Price Growth
BFRI (@Pharmaceuticals: Generic) experienced а +3.73% price change this week, while CTOR (@Pharmaceuticals: Generic) price change was +2.14% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.13%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was +10.54%.
Reported Earning Dates
BFRI is expected to report earnings on Nov 13, 2026.
CTOR is expected to report earnings on Dec 22, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.13% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
BFRI and
Correlation & Price change
A.I.dvisor tells us that BFRI and CTOR have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BFRI and CTOR's prices will move in lockstep.
| Ticker / NAME | Correlation To BFRI | 1D Price Change % | ||
|---|---|---|---|---|
| BFRI | 100% | +1.02% | ||
| CTOR - BFRI | 26% Poorly correlated | -0.71% | ||
| ACET - BFRI | 25% Poorly correlated | -0.33% | ||
| KMDA - BFRI | 24% Poorly correlated | +0.37% | ||
| SBFM - BFRI | 23% Poorly correlated | -3.51% | ||
| LNTH - BFRI | 23% Poorly correlated | -0.02% | ||
More | ||||
CTOR and
Correlation & Price change
A.I.dvisor tells us that CTOR and BFRI have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CTOR and BFRI's prices will move in lockstep.
| Ticker / NAME | Correlation To CTOR | 1D Price Change % | ||
|---|---|---|---|---|
| CTOR | 100% | -0.71% | ||
| BFRI - CTOR | 25% Poorly correlated | +1.02% | ||
| PRGO - CTOR | 25% Poorly correlated | -1.66% | ||
| IMCC - CTOR | 22% Poorly correlated | -6.05% | ||
| RDHL - CTOR | 21% Poorly correlated | -2.43% | ||
| HIMS - CTOR | 21% Poorly correlated | +8.78% | ||
More | ||||